News | June 23, 2015

Accuray Initiates International Commercial Launch of the InCise Multileaf Collimator

Add-on to robotic CyberKnife M6 System launched following evaluation in the Netherlands

Accuray, CyberKnife M6, InCise MLC, collimator, international launch

Image courtesy of Accuray Inc.

June 23, 2015 - Accuray Inc. announced in April that the InCise Multileaf Collimator (MLC) for the CyberKnife M6 System is available outside the United States in markets where it is approved for sale. The InCise MLC was launched in the U.S. market in February.

The launch follows the successful completion of the evaluation of the InCise MLC by Erasmus MC Cancer Institute in Rotterdam, the Netherlands, the European evaluation site working in collaboration with Accuray. Two sites in the U.S. had previously completed their successful evaluation of the InCise MLC. The main benefits of the MLC reported by the sites were the ability to treat a broader range of tumors than they could with fixed collimators or the Iris Collimator, and to do so with significantly increased efficiency. The InCise MLC was featured at the European Society for Therapeutic Radiology and Oncology (ESTRO) meeting in Barcelona, Spain, April 24 – 27.

The InCise MLC is one of the world's first multileaf collimators to be available on a robotic platform, the CyberKnife M6 System. The system's robotic design enables physicians to find the best angles for radiation to enter and exit the body, thus maximizing dose to the target while minimizing exposure to healthy tissue. The robotic design also enables the system to adjust and automatically stay on target in real-time, accounting for patient and tumor motion.

The CyberKnife M6 System can be used to treat tumors anywhere in the body, including the prostate, lung, brain, spine, liver, pancreas and kidney, and may offer hope to patients who have inoperable or surgically complex tumors, or who may prefer a clinically effective, non-surgical option.

For more information: www.accuray.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...